

Author Index

VOLUME 21, 2003

Adamson, David, 223
Arici, Aydin, 109, 135, 165
Azziz, Ricardo, 295

Barnes, Randall B., 285
Bossuyt, Patrick M.M., 17
Bradshaw, Karen D., 327, 339, 353
Bruner-Tran, Kaylon L., 155
Bulun, Serdar E., 125

Carr, Bruce R., 1, 107, 263, 325
Collins, John A., 3, 49, 95
Coutifaris, Christos, 265, 317

Davis, O.K., 65
Daya, Salim, 73
Debrock, Sophie, 243
D'Hooghe, Thomas M., 243
Donnez, Jacques, 235
Driscoll, Deborah A., 301
Duleba, Antoni J., 193

Ehrmann, David A., 277
Eijkemans, M.J.C., 39
Evers, Johannes L.H., 9, 17

Fausser, B.C.J.M., 39
Fazleabas, Asgerally T., 255
Foster, Warren G., 145
Fritz, Marc A., 27

Garcia-Velasco, Juan A., 165
Garrido, Nicolás, 183
Gell, Jennifer S., 375
Giudice, Linda C., 119
Groll, Jeremy M., 27
Gurates, Bilgin, 125
Guzick, David, 309

Habbema, J.D.F., 39
Hastings, Julie M., 255
Heroux, Kimberly, 389
Hill, Joseph A., 243
Hoffman, Barbara, 353
Hughes, Edward G., 55

Jabara, Sami, 317
Jadoul, Pascale, 235

Kakarla, Nirupama, 339
Kashyap, S., 65
Kass-Wolff, Jane, 329
Kennedy, Stephen, 111

Land, Jolande A., 9
Legro, Richard S., 267
Lijmer, Jeroen G., 17
Liu, James H., 5

Meuleman, Christel, 243
Minjarez, Debra A., 363

Mol, Ben W., 9, 17
Moran, Carlos, 295

Neithardt, Adrienne B., 285

Olive, David L., 209
Osteen, Kevin G., 155

Pellicer, Antonio, 183
Pirard, Céline, 235


Remohí, José, 183
Rier, Sherry, 145
Rychlik, Daniel, 277

Schlesselman, James J., 95
Seli, Emre, 135
Simón, Carlos, 183
Smets, Mireille, 235
Spaczynski, Robert Z., 193
Squifflet, Jean, 235
Sukalich, Sara, 309
Sulak, Patricia J., 399

Van Steirteghem, André, 49
Van Voorhis, Bradley J., 85

Wilson, Ellen E., 329
Witz, Craig A., 173

Yeaman, Grant R., 155



Subject Index

VOLUME 21, 2003

- Absolute numbers, in randomized clinical trials (RCT), clinical research *vs.* medical practice, 55–64
- Acanthosis nigricans, polycystic ovary syndrome (PCOS) and, 271–273
- Acne, polycystic ovary syndrome (PCOS), pharmacologic treatment, 277–282
- Acquired immunodeficiency syndrome (AIDS), in adolescent patients, 407–408
- Adolescent patients. *See also* Pediatric gynecology
abnormal bleeding in, 363–372
contraceptive choices for chronically ill patients, 389–398
delayed puberty and amenorrhea, 353–361
polycystic ovary syndrome (PCOS), 301–306
pubertal developmental disorders, 339–350
sexually transmitted disease (STD) in, 399–411
- Adrenal hyperplasia, in polycystic ovary syndrome (PCOS) patients, 295–299
- Amenorrhea, delayed puberty and, 353–361
- Androgen excess. *See* Hyperandrogenism
- Androgen receptor antagonists, for polycystic ovary syndrome (PCOS) patients, 289–291
- Angiogenesis inhibitors, endometriosis therapy using, 212–218
- Animal models, endometriosis research, 150–151, 255–260
- Anovulation
abnormal bleeding in adolescents, 363–372
clomiphene citrate therapy, outcome predictions, 39–46
polycystic ovary syndrome (PCOS), 267–273
- Antiandrogens, polycystic ovary syndrome (PCOS), hirsutism diagnosis and management, 285–291
- Apoptosis, endometriosis pathogenesis and, 165–170
- Aromatase, endometriosis pathophysiology, 125–132
- Aromatase inhibitors
endometriosis pathophysiology, 125–132
endometriosis therapy using, 212–218
- Assisted reproduction therapy (ART), intracytoplasmic sperm injection *vs.* in vitro fertilization, evidence-based research, 49–54
- Autoantibodies, endometriosis and, 137–141
- Bcl-2/bax genes, apoptosis and endometriosis pathogenesis, 165–170
- Bias, causation study guidelines and, 73–83
- Bioinformatics, endometriosis research and, 260
- Blood dyscrasia, abnormal bleeding in adolescents and, 365–370
- Breast disease, contraception for medically ill adolescent patients and risk of, 390–398
- Cadherins, endometriosis and, 175–178
- CA-125 marker, endometriosis diagnosis, 193–202
- Cardiovascular health
contraception for medically ill adolescent patients, 390–398
polycystic ovary syndrome (PCOS) and, 309–314
- Case control studies
causation study guidelines and, 73–83
diagnostic studies using, 20–25
- Causation studies, guidelines for, 73–83
- cDNA microarray analysis, endometriosis research and, 259–260
- Cell adhesion molecules (CAMs), endometriosis and, 173–179
apoptosis pathways, 168–170
- Cervicitis, abnormal bleeding in adolescents and, 365–370
- Chlamydia, in adolescent patients, 402–403
- Chlamydia antibody test (CAT), evidence-based diagnosis and, 9–14
- Clinical research. *See also* Randomized clinical trials (RCT)
diagnostic research, evidence-based strategies, 9–14
evidence-based search strategies, 5–8
medical therapy for endometriosis and, 209–218
randomized clinical trials (RCT) and medical practice *vs.*, 55–64
systematic review and meta-analysis of, 95–104
- Clomiphene citrate therapy, ovulation induction, outcome predictions, 39–46
- Coagulation disorders, polycystic ovary syndrome (PCOS) patients and, 311–314
- Cohort studies
causation study guidelines, 73–83
diagnostic studies using, 20–25
- Condom use, sexually transmitted disease (STD) in adolescents and, 399–411
- Condyloma acuminata
abnormal bleeding in adolescents and, 366–370
in pediatric patients, 336–337
- Confounding variables, causation study guidelines, 73–83
- Contraception. *See also* Oral contraceptives
for medically ill adolescent patients, 389–398
sexually transmitted disease (STD) in adolescents and, 399–411
- Contrasexual development, in pediatric patients, 349–350
- Coronary heart disease (CHD)
contraception for medically ill adolescent patients, 390–398
polycystic ovary syndrome (PCOS) and risk of, 309–314
prognosis studies, literature evaluation for, 27–35

- Cost-effectiveness, economics studies evaluation, 85-92
- Cytokines
- endometriosis pathophysiology and, 135-141
 - matrix metalloproteinases, endometriosis pathophysiology, 155-160
- Danazol, endometriosis therapy using, 209-218
- Delayed puberty, amenorrhea and, 353-361
- Diabetes mellitus, contraception for medically ill adolescent patients, 390-398. *See also* Type 2 diabetes mellitus
- Diagnostic studies
- characteristics of, 17-25
 - endometriosis, 193-202
 - evidence-based guidelines for, 9-14
 - pediatric gynecology, 329-337
 - polycystic ovary syndrome (PCOS), 267-273
 - 21-hydroxylase-deficient nonclassic adrenal hyperplasia, differential diagnosis, 295-299
- Diagnostic testing, causation study guidelines and, 73-83
- Differential diagnoses
- endometriosis, 193-202
 - evidence-based strategies for, 9-14
 - polycystic ovary syndrome (PCOS), 267-273
 - 21-hydroxylase-deficient nonclassic adrenal hyperplasia and, 295-299
- Dioxins/dioxin-like polychlorinated biphenyls, endometriosis pathogenesis and, 145-151
- DNA markers, endometriosis genetics, 111-117
- Ductal system development, Müllerian anomalies, 377-387
- Dyslipidemia
- contraception for medically ill adolescent patients, 390-398
 - polycystic ovary syndrome (PCOS) and cardiovascular health, 309-314
- Economics studies, evaluation of, 85-92
- Ectopic endometrium
- gene/protein expression, 122-123
 - research issues involving, 255-260
- Ectopic hormone production, pubertal developmental disorders and, 349
- Embryo status, in endometriosis, 183-189
- Endocrine system
- endometriosis pathophysiology and, 135-141
 - environmental contaminants and endometriosis, 145-151
- Endometriomas, surgical management of, 223-230
- Endometriosis
- apoptosis and pathogenesis of, 165-170
 - cell-adhesion molecules, 173-179
 - differential diagnosis, 193-202
 - environmental dioxins and, 145-151
 - future research issues, 255-260
 - genetics and positional cloning, 111-117
 - hormonal factors in, 125-132
 - immune/endocrine system interaction, 135-141
 - matrix metalloproteinases and, 155-160
 - medical therapy, 209-218
 - pathogenesis, genomic studies, 119-123
 - subfertility and, 243-251
 - surgical management of, 223-230
 - surgical management of, pre- and post-surgical protocols, 235-240
 - uterine and ovarian function, 183-189
- Environmental contaminants
- endometriosis and, 145-151
 - matrix metalloproteinases, endometriosis pathophysiology, 155-160
- Estradiol, endometriosis pathophysiology, 125-132
- Estrogen
- endometriosis pathophysiology, 125-132
 - endometriosis therapy using, 212-218
 - matrix metalloproteinases, endometriosis pathophysiology, 155-160
- Estrogen receptor (ER β), endometriosis research and, 255-260
- Estrone, endometriosis pathophysiology, 125-132
- Eutopic endometrium
- apoptosis and endometriosis pathogenesis, 165-170
 - endometriosis and function of, 186-189
 - gene/protein expression, 122-123
 - research issues involving, 255-260
- Evidence-based research guidelines
- diagnostic issues, 9-14
 - prognosis studies, 27-35
 - therapeutic options and, 5-8
 - in vitro fertilization trials, 49-54
- Exercise/dieting, abnormal bleeding in adolescents and, 371-372
- Extracellular matrix (ECM), endometriosis and
- apoptosis pathways, 165-170
 - cell adhesion molecules (CAMs), 173-179
- Familial male precocious puberty, pathophysiology, 348-349
- Fas/fas ligands, apoptosis and endometriosis pathogenesis, 165-170
- Femal genital anatomy
- delayed puberty and defects in, 359-361
 - Müllerian anomalies, 375-387
 - in pediatric patients, 329-333
 - pubertal developmental disorders and, 340-343
- Fertility drugs, ovarian cancer risk and, 65-71
- Genetics studies. *See also* Proteomics
- apoptosis and endometriosis pathogenesis, 165-170
 - endometriosis, positional cloning, 111-117
- Genital herpes, in adolescent patients, 405-406
- Genital human papillomavirus, in adolescent patients, 406-407
- Genomics, endometriosis pathogenesis, 119-123
- Gestrinone, endometriosis therapy using, 211-218
- Glucocorticoids, for polycystic ovary syndrome (PCOS) patients, 289-291
- GnRH agonists/antagonists
- endometriosis therapy using, 211-218
 - for polycystic ovary syndrome (PCOS) patients, 289-291
- Gonadotropin-dependent precocious puberty, 345-347
- Gonadotropin-independent precocious puberty, 347-349
- Gonadotropin-releasing hormone (GnRH), pubertal developmental disorders, 339-350
- Gonorrhea, in adolescent patients, 403-404

- Hair removal, polycystic ovary syndrome (PCOS), hirsutism
diagnosis and management, 285-291
- Hirsutism, polycystic ovary syndrome (PCOS)
adolescent patients, 301-306
diagnosis and management, 285-291
pharmacologic treatment, 277-282
- Hormone function
delayed puberty and, 353-361
endometriosis pathophysiology and, 125-132
medical therapy for endometriosis and, 209-218
polycystic ovary syndrome (PCOS), adolescent patients,
301-306
pubertal developmental disorders, 339-350
- Human immunodeficiency virus (HIV), in adolescent
patients, 407-408
- Humoral immune response, endometriosis and, 137-141
- 21-Hydroxylase-deficient nonclassic adrenal hyperplasia
(NCAH), polycystic ovary syndrome (PCOS),
differential diagnosis, 295-299
- 17 β -Hydroxysteroid dehydrogenase (HSD) type 2,
endometriosis pathophysiology, 125-132
- Hyperandrogenism, polycystic ovary syndrome (PCOS),
267-273
adrenal hyperplasia and, 295-299
hirsutism diagnosis and management, 285-291
- Hypercoagulation, contraception for medically ill adolescent
patients, 390-398
- Hypergonadotropic hypogonadism, delayed puberty and,
356-361
- Hyperprolactinemia, abnormal bleeding in adolescents and,
371-372
- Hypertension
contraception for medically ill adolescent patients,
390-398
in polycystic ovary syndrome (PCOS) patients, 310-314
- Hypogonadotropic hypogonadism, delayed puberty and,
355-361
- Hypothalamic-pituitary-ovarian (HPO) axis
abnormal bleeding in adolescents and, 363-372
precocious puberty diagnosis and pathophysiology,
339-350
- Hypothyroidism, abnormal bleeding in adolescents and,
371-372
- Hysterosalpingography, evidence-based diagnostic strategies,
9-14
- Imaging studies, endometriosis diagnosis, 193-202
- Immune response
endometriosis pathophysiology and, 135-141
environmental contaminants and endometriosis, 145-151
- Immunoglobulin superfamily, endometriosis and, 175-178
- Immunomodulation, endometriosis research and, 255-260
- Imperforate hymen, in pediatric patients, 333-335
- Implantation mechanisms, endometriosis pathogenesis,
119-123
- Index tests, diagnostic studies and, 17-25
- Infertility. *See also* In vitro fertilization/embryo transfer (IVF-
ET); Subfertility
economics studies evaluation, 85-92
endometriosis, medical therapy for, 209-218
in polycystic ovary syndrome (PCOS) patients, 279-283,
317-323
surgical management of endometriosis and, 223-230
uterine and ovarian function with endometriosis and,
183-189
- Inflammatory disease, endometriosis research and, 255-260
- Inheritance studies, polycystic ovary syndrome (PCOS),
298-299
- Insulin resistance
polycystic ovary syndrome (PCOS), 267-273
cardiovascular health and, 309-314
polycystic ovary syndrome (PCOS), pharmacologic
treatment, 277-282
- Integrins, endometriosis and, 174-178
- "Intent to treat" analysis, randomized clinical trials (RCT)
and clinical research *vs.*, 55-64
- Intracytoplasmic sperm injection (ICSI), *vs.* in vitro
fertilization, evidence-based research, 49-54
- In vitro fertilization/embryo transfer (IVF-ET)
clinical trials, evidence-based research guidelines, 49-54
economics studies evaluation, 85-92
endometriosis pathogenesis, 119-123
ovarian and uterine function in endometriosis and,
183-189
ovarian cancer risk and, 65-71
in polycystic ovary syndrome (PCOS) patients, 317-323
- Kallmann syndrome, delayed puberty and, 355-361
- Klinefelter's syndrome, delayed puberty and, 357-361
- Labial adhesions, in pediatric patients, 333-335
- Laparoscopy
endometriosis diagnosis, 193-202
evidence-based diagnostic strategies using, 9-14
- Lateral fusion, Müllerian anomalies and, 385-387
- Likelihood ratios, in diagnostic studies, 17-25
- Literature resources
evaluation of, for prognosis strategies, 27-35
evidence-based search strategies, 5-8
ovarian cancer risk and fertility drugs, evaluation of
literature on, 65-71
systematic review and meta-analysis of, 95-104
- Luteinizing hormone, polycystic ovary syndrome (PCOS)
and in vitro fertilization, 318-323
- Lymphocytes, endometriosis and, 137-141
- Matrix metalloproteinases
endometriosis pathophysiology and, 155-160
inhibitors, endometriosis therapy with, 213-218
- McCune-Albright syndrome, in pediatric patients,
347-348
- Medical practices and procedures
economics studies evaluation and, 85-92
endometriosis therapy, 209-218
randomized clinical trials (RCT) and clinical research *vs.*,
55-64
systematic review and meta-analyses concerning, 95-104
- Medical search engine design, evidence-based search
strategies, 5-8
- Menorrhagia, abnormal bleeding in adolescents, 363-372

- Menstruation cycle
abnormal bleeding in adolescents, 363-372
delayed puberty and amenorrhea, 353-361
endometrial environment during, 159-160
matrix metalloproteinase expression during, 155-160
polycystic ovary syndrome (PCOS), adolescent patients, 301-306
retrograde menstruation, endometriosis pathophysiology, 135-141
- Mental disability, contraception for medically ill adolescent patients, 390-398
- Meta-analysis, evaluation of, 95-104
- Metformin, prognosis studies, literature evaluation for, 27-35
- Molecular targeting, medical therapy for endometriosis and, 209-218
- Monocyte chemotactic protein-1 (MCP-1), endometriosis and, 137-141
- Monthly fecundity rate (MFR), subfertility and endometriosis, 243-251
- Müllerian anomalies, diagnosis and pathophysiology, 375-387
abnormal bleeding in adolescents and, 367-370
- Natural killer cells, endometriosis pathophysiology, 135-141
- Normogonadotropic oligoamenorrheic infertility, clomiphene citrate therapy, outcome predictions, 39-46
- Obesity, polycystic ovary syndrome (PCOS) patients and, 309-314
- Odds ratios, causation study guidelines, 73-83
- Oligomenorrhea, polycystic ovary syndrome (PCOS) therapy, 277-282
- Oocyte alteration, in endometriosis, 183-189
- Oocyte implantation, in polycystic ovary syndrome (PCOS) patients, 317-323
- Oral contraceptives
endometriosis therapy using, 210-218
for medically ill adolescent patients, 389-398
for polycystic ovary syndrome (PCOS) patients, 288-291
- Oral glucose tolerance test (OGTT), in polycystic ovary syndrome (PCOS) patients, 267-273, 277-283
- Outcome prediction, economics studies evaluation and, 85-92
- Ovarian cancer, fertility drugs and, 65-71
- Ovarian endometriosis, surgical management of, 235-240
- Ovarian function
abnormal bleeding in adolescents and, 369-371
in endometriosis, 183-189
genetic factors in endometriosis and, 111-117
polycystic ovary syndrome (PCOS) and, 268-273
- Ovarian hyperstimulation syndrome, in polycystic ovary syndrome (PCOS) patients, 317-323
- Ovarian suppression, endometriosis management, surgical therapy *vs.*, 223-231
- Ovulation induction
clomiphene citrate therapy, outcome predictions, 39-46
ovarian cancer risk and, 65-71
- Pediatric gynecology
abnormal bleeding in adolescents, 363-372
assessment strategies and issues, 329-337
contraception for medically ill adolescent patients, 389-398
delayed puberty and amenorrhea, 353-361
Müllerian anomalies, 375-387
pubertal developmental disorders, 339-350
sexually transmitted diseases (STDs), 399-411
- Pelvic examination, endometriosis diagnosis and, 193-202
- Pelvic inflammatory disease (PID), in adolescent patients, 404-405
- Pelvic pain
medical therapy for endometriosis and, 209-218
surgical management of endometriosis and, 223-230
- Pentoxifylline, endometriosis therapy using, 213-218
- Peritoneal fluid, endometriosis and function of, 184-189
- Pharmacology, polycystic ovary syndrome (PCOS) therapy, 277-282
- PICO (Patient-Intervention-Comparison-Outcome)
research strategy, differential diagnosis and, 9-14
- Polycystic ovary syndrome (PCOS)
adolescent patients, 301-306
cardiovascular health and, 309-314
diagnostic criteria, 267-273
hirsutism diagnosis and management, 285-291
21-hydroxylase-deficient nonclassic adrenal hyperplasia, differential diagnosis, 295-299
pharmacologic therapy, 277-282
prognosis studies, literature evaluation for, 27-35
in vitro fertilization/embryo transfer (IVF-ET) and, 317-323
- Positional cloning techniques, endometriosis genetics, 111-117
- Postoperative protocols, surgical management of endometriosis, 235-240
- Precocious puberty, diagnosis and pathophysiology, 339-350
- Pregnancy, abnormal bleeding in adolescents and, 364-370
- Pregnancy rates, subfertility and endometriosis, 243-251
- Preoperative protocols, surgical management of endometriosis, 235-240
- Prepubertal reproductive anatomy, assessment strategies and issues, 329-337
- Prevalence studies, subfertility and endometriosis, 243-251
- Progesterone
endometriosis pathophysiology, 125-132
matrix metalloproteinases, endometriosis pathophysiology, 155-160
- Progesterone receptor, endometriosis pathophysiology, 125-132
- Progestogens, endometriosis therapy using, 210-218
- Prognosis studies
evidence-based strategies and literature evaluation, 27-35
treatment outcome predictions, 39-46
- Proinflammatory cytokines, matrix metalloproteinases, endometriosis pathophysiology, 155-160
- Proportions, in randomized clinical trials (RCT), clinical research *vs.* medical practice, 55-64
- Proteins, endometriosis and ECM proteins, 176-178
- Proteomics. *See also* Genetics studies; Genomics
endometriosis pathogenesis, 119-123
- Pubertal developmental disorders
delayed puberty and amenorrhea, 353-361
polycystic ovary syndrome (PCOS) in adolescence and, 301-306
precocious puberty, 339-350

- Randomized clinical trials (RCT)
causation study guidelines, 73-83
in diagnostic studies, 17-25
medical practice *vs.* clinical research involving, 55-64
prognosis studies, literature evaluation for, 27-35
systematic review and meta-analysis of, 95-104
in vitro fertilization, evidence-based research, 49-54
RANTES cytokine, endometriosis and, 137-141
Reference tests, diagnostic studies and, 17-25
Relative risks, causation study guidelines, 73-83
Renal disease, contraception for medically ill adolescent patients, 390-398
Research protocols
endometriosis and subfertility, 245-251
endometriosis research, 255-260
environmental contaminants, 145-151
evidence-based research guidelines
diagnostic issues, 9-14
prognosis studies, 27-35
therapeutic options and, 5-8
in vitro fertilization trials, 49-54
literature evaluations
ovarian cancer risk and fertility drugs, evaluation of literature on, 65-71
systematic review and meta-analysis of, 95-104
Retrograde menstruation, endometriosis pathophysiology, 135-141
Risk difference, systematic review and meta-analysis of, 95-104
Rokitansky-Kuster-Hauser syndrome, Müllerian anomalies, 379-387
RU486, endometriosis therapy using, 211-218
Sampson's theory of retrograde menstruation, endometriosis pathophysiology and, 135-141
Selectins, endometriosis and, 175-178
Sensitivity in testing, diagnostic studies and, 17-25
Sexual abuse, pediatric gynecology and, 329-337
Sexual differentiation, Müllerian anomalies, 375-387
Sexually acquired hepatitis, in adolescent patients, 408-409
Sexually transmitted disease (STD), in adolescents, 399-411
Specificity in testing, diagnostic studies and, 17-25
Steroid hormones, endometriosis and, 258-260
Steroidogenesis, endometriosis pathophysiology, 125-132
Subfertility. *See also* Infertility
endometriosis and, 243-251
Surgical procedures
endometriosis diagnosis, 201-202
endometriosis management
medical therapy following, 216-218
pre- and post-surgical guidelines, 235-240
endometriosis therapy using, 223-230
Syphilis, in adolescent patients, 401-402
Systematic review, evaluation of, 95-104
Systemic lupus erythematosus (SLE), contraception for medically ill adolescent patients, 390-398
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD),
endometriosis pathogenesis and, 145-151
Therapeutic strategies, evidence-based guidelines for, 5-8
Thromboembolism history, contraception for medically ill adolescent patients, 390-398
Tissue inhibitors of metalloproteinases (TIMPs),
endometriosis and, 155-160
Transplantation theory, apoptosis and endometriosis pathogenesis, 165-170
Trichomoniasis, in adolescent patients, 400-401
Tubal factor subfertility, evidence-based diagnosis of, 9-14
Tumor necrosis factor (TNF)- α inhibitors, endometriosis therapy using, 212-218
Turner's syndrome, delayed puberty and, 357-361
Type 2 diabetes mellitus. *See also* Diabetes mellitus
Type 2 diabetes mellitus, polycystic ovary syndrome (PCOS) and, 277-282
Ultrasonography, polycystic ovary syndrome (PCOS), 267-273
Urethral prolapse, in pediatric patients, 336-337
Uterine function
abnormal bleeding in adolescents and, 367-370
in endometriosis, 183-189
endometriosis research and receptivity studies, 255-260
Müllerian anomalies, 375-387
Vaginal septum, Müllerian anomalies, 375-387
Vaginitis, abnormal bleeding in adolescents and, 366-370
Vascular endothelial growth factor (VEGF), endometriosis and, 141
Verification bias, in diagnostic studies, 21-25
Vertical fusion, Müllerian anomalies and, 383-387
Vulvitis, in prepubertal patients, 329-337
Vulvovaginitis, in prepubertal patients, 329-337
Y chromosome disorders, Müllerian anomalies, 375-387